CSL Biotherapies, Inc. announced today that shipment of its seasonal influenza vaccine for the 2013-2014 season has started.
"Given the magnitude of influenza burden in the U.S. and the unpredictability of seasonal outbreaks, timely delivery of flu vaccines is more critical now than ever before," said Dr. Marie Mazur, Head of Worldwide Commercial Operations, Influenza. "CSL Biotherapies is committed to addressing this public health need by consistently delivering its influenza vaccine early to the healthcare providers in the United States."
CSL Biotherapies will ship approximately 10 million doses of the seasonal flu vaccine to the United States for the upcoming season. Shipment will comprise multi-dose and pre-filled syringe presentations.